Poly(ADP-ribose) polymerase (PARP) inhibitors emerged as the first targeted treatment for ovarian cancer, and are selectively active for women with mutations in BRCA1 and BRCA2 (mBRCA). On the basis of data showing activity (measured by the proportion of patients who achieved an objective response),¹ the PARP inhibitor olaparib received US Food and Drug Administration (FDA) approval in 2014 specifically for women with germline mBRCA-associated (gBRCA) recurrent ovarian cancer.² However, subsequent findings from clinical trials of PARP inhibitors have suggested that the importance of mBRCA as a predictive biomarker has diminished.

中文翻译：

---

用于卵巢癌靶向治疗的PARP抑制剂

聚（ADP-核糖）聚合酶（PARP）抑制剂是卵巢癌的首个靶向治疗药物，对具有BRCA1和BRCA2突变（mBRCA）的女性具有选择性活性。根据显示活性的数据（以达到客观缓解的患者比例衡量），¹ PARP抑制剂olaparib于2014年获得了美国食品药品监督管理局（FDA）的批准，专门针对复发性mBRCA相关（gBRCA）的女性卵巢癌。²然而，PARP抑制剂临床试验的后续发现表明，mBRCA作为预测性生物标志物的重要性已降低。